UK reviews Palantir's £330M NHS contract as break clause pressure grows

Britain is reassessing its reliance on Palantir Technologies for National Health Service data analytics, putting a £330 million contract at risk of termination.

Britain launched a full review of its National Health Service contract with Palantir Technologies, as political pressure mounts for the government to trigger a break clause on the £330 million ($441 million) deal when its initial term expires in early 2027.

"The current health secretary is reviewing every single aspect of that contract to make sure we get the right deal for Britain," Technology Minister Liz Kendall told Times Radio on Tuesday, citing concerns about patient confidentiality, public trust and reliance on a U.S. supplier.

The contract, awarded in 2023 to build a platform linking NHS data, runs until early 2027, when the government must decide whether to extend it for up to seven years or terminate it. A parliamentary committee last week urged ministers to end the deal, warning Palantir's growing role represents an "unacceptable point of weakness" and highlighting risks from depending on a small number of U.S. tech firms.

The review threatens one of Palantir's highest-profile government contracts in Europe and comes as the company faces broader political headwinds in the UK. London Mayor Sadiq Khan last month blocked a separate £50 million police contract with Palantir, citing concerns about value for money and whether companies' ethics should be considered in public procurement.

The parliamentary committee acknowledged that NHS officials reported benefits from Palantir's software in areas such as waiting list management, operations and hospital discharge planning. But it warned that the company's connections to the U.S. military and immigration authorities, along with the political views of its billionaire co-founder Peter Thiel — an early supporter of President Donald Trump — raised questions about the handling of sensitive health data.

Last month, the Financial Times reported that NHS officials had proposed granting some external staff, including Palantir personnel, broad administrative access to identifiable patient data on parts of the system. Campaigners and unions have warned against the partnership, stressing the need to evaluate the ethics of companies involved in public procurement.

Palantir's Expanding UK Government Footprint

The NHS contract review comes as Palantir's presence across UK public services has drawn increasing scrutiny. The company's software is used by multiple government departments, and the parliamentary committee warned that this growing dependence on a single U.S. supplier creates vulnerabilities in critical national infrastructure.

Palantir has defended its work, saying its software helps improve patient care and efficiency across the NHS. The company has not yet responded to requests for comment on the review.

The review also creates potential headwinds for other U.S. technology firms operating in UK public sectors. The government's decision on the Palantir contract — whether to extend or terminate in early 2027 — will be closely watched by technology companies with government contracts in Britain.

This article is for informational purposes only and does not constitute investment advice.